Zacks: Brokerages Expect Pacira Pharmaceuticals Inc (PCRX) to Announce $0.23 EPS

Equities analysts expect that Pacira Pharmaceuticals Inc (NASDAQ:PCRX) will report $0.23 earnings per share for the current quarter, according to Zacks. Seven analysts have made estimates for Pacira Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.35 and the lowest estimate coming in at $0.04. Pacira Pharmaceuticals posted earnings of $0.38 per share during the same quarter last year, which indicates a negative year-over-year growth rate of 39.5%. The firm is expected to announce its next quarterly earnings report on Wednesday, February 27th.

On average, analysts expect that Pacira Pharmaceuticals will report full year earnings of $0.81 per share for the current year, with EPS estimates ranging from $0.60 to $0.92. For the next fiscal year, analysts expect that the business will post earnings of $1.28 per share, with EPS estimates ranging from ($0.30) to $1.87. Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that cover Pacira Pharmaceuticals.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its earnings results on Thursday, November 1st. The company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.40. Pacira Pharmaceuticals had a negative net margin of 1.30% and a positive return on equity of 2.74%. The company had revenue of $83.45 million for the quarter, compared to the consensus estimate of $79.87 million. During the same period in the previous year, the firm earned $0.11 earnings per share. Pacira Pharmaceuticals’s quarterly revenue was up 23.9% compared to the same quarter last year.

PCRX has been the topic of a number of analyst reports. Needham & Company LLC set a $60.00 target price on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, November 1st. Piper Jaffray Companies set a $55.00 target price on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, November 1st. ValuEngine raised shares of Pacira Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, October 18th. Royal Bank of Canada set a $55.00 target price on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, September 19th. Finally, JMP Securities lifted their target price on shares of Pacira Pharmaceuticals from $56.00 to $63.00 and gave the stock a “buy” rating in a research note on Thursday, November 1st. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and nine have assigned a buy rating to the stock. Pacira Pharmaceuticals presently has an average rating of “Hold” and an average target price of $53.76.

PCRX stock traded down $0.18 during trading on Friday, reaching $48.14. 404,654 shares of the stock were exchanged, compared to its average volume of 783,006. The company has a debt-to-equity ratio of 0.95, a current ratio of 8.66 and a quick ratio of 7.83. Pacira Pharmaceuticals has a 1 year low of $26.95 and a 1 year high of $55.00. The company has a market capitalization of $1.99 billion, a PE ratio of -83.00, a price-to-earnings-growth ratio of 82.60 and a beta of 1.65.

In other news, VP Lauren Bullaro Riker sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, November 2nd. The shares were sold at an average price of $54.35, for a total value of $54,350.00. Following the sale, the vice president now directly owns 11,474 shares of the company’s stock, valued at approximately $623,611.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gary W. Pace purchased 4,000 shares of Pacira Pharmaceuticals stock in a transaction dated Wednesday, November 7th. The stock was bought at an average cost of $51.29 per share, for a total transaction of $205,160.00. Following the completion of the purchase, the director now directly owns 28,319 shares in the company, valued at approximately $1,452,481.51. The disclosure for this purchase can be found here. Insiders sold a total of 151,221 shares of company stock worth $7,403,146 over the last three months. Insiders own 5.90% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Granahan Investment Management Inc. MA raised its stake in shares of Pacira Pharmaceuticals by 12.3% in the 2nd quarter. Granahan Investment Management Inc. MA now owns 188,086 shares of the company’s stock valued at $6,028,000 after acquiring an additional 20,617 shares during the period. Mutual of America Capital Management LLC raised its stake in shares of Pacira Pharmaceuticals by 15.3% in the 2nd quarter. Mutual of America Capital Management LLC now owns 155,554 shares of the company’s stock valued at $4,986,000 after acquiring an additional 20,606 shares during the period. Mizuho Securities USA LLC raised its stake in shares of Pacira Pharmaceuticals by 193.8% in the 3rd quarter. Mizuho Securities USA LLC now owns 23,500 shares of the company’s stock valued at $1,155,000 after acquiring an additional 15,500 shares during the period. Russell Investments Group Ltd. raised its stake in shares of Pacira Pharmaceuticals by 14.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 56,610 shares of the company’s stock valued at $1,813,000 after acquiring an additional 7,249 shares during the period. Finally, United Services Automobile Association grew its holdings in shares of Pacira Pharmaceuticals by 10.9% in the second quarter. United Services Automobile Association now owns 127,822 shares of the company’s stock valued at $4,097,000 after purchasing an additional 12,600 shares in the last quarter. 97.84% of the stock is currently owned by institutional investors and hedge funds.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Featured Story: The Discount Rate – What You Need to Know

Get a free copy of the Zacks research report on Pacira Pharmaceuticals (PCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply